Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

The alkylating agent temozolomide (TMZ) together with maximal safe bulk resection and focal radiotherapy comprises the standard treatment for glioblastoma (GB), a particularly aggressive and lethal primary brain tumor. GB affects 3.2 in 100,000 people who have an average survival time of around 14 m...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Biomedicines
Päätekijät: Strobel, Hannah, Baisch, Tim, Fitzel, Rahel, Schilberg, Katharina, Siegelin, Markus D., Karpel-Massler, Georg, Debatin, Klaus-Michael, Westhoff, Mike-Andrew
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2019
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6783999/
https://ncbi.nlm.nih.gov/pubmed/31505812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines7030069
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia